Table 3.
Comparison of Cytogenetics of AML Patients between Our Study and Other Studies
| Reference | Our study | Enjeti | Meng | Cheng | Wakui | Udupa | Elnaggar 2022 | Gmidene | Khoubila | Grimwade | Byrd |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | 2004 | 2013 | 2009 | 2008 | 2020 | 2012 | 2019 | 2010 | 2002 | ||
| Country | Vietnam | Singapore | Malaysia | China | Japan | India | Egypt | Tunisia | Morocco | UK | USA |
| No. of cases (n) | 336 | 454 | 480 | 1432 | 638 | 173 | 120 | 631 | 895 | 5876 | 1311 |
| Median age (range) | 39 (1-81) |
49 (15-100) |
39 (0.3-81) |
42 (4-84) |
45 (15-66) |
39 (16-82) |
36.5 (18-86) |
37 (0.08-95) |
40.5 (20-60) |
44 (15-59) |
52 (15-86) |
| Normal karyotype, n (%) | 38.1 | 39 | 69.6 | 42 | 41.8 | 34.6 | 56.7 | 37.1 | 42 | 41 | 48 |
| Structural abnormalities (%) | |||||||||||
| t(15;17) | 19.6 | 11 | 2.3 | 14 | - | 8.6 | 9.2 | 13.2 | 3.7 | 13 | 7 |
| t(8;21) | 10.1 | 7.5 | 7.5 | 8 | 17.7 | 20.8 | 7.5 | 12.2 | 12.5 | 7 | 8.7 |
| inv(16) | 6.3 | 1.1 | - | 4.1 | 17.9 | 7.5 | 3.8 | 3.3 | 5 | 7.9 | |
| 11q23 abn | 1.5 | 0.9 | - | 1 | 5 | 3.4 | 7.5 | 3.5 | 3.6 | 3.6 | - |
| inv(3) | 1.2 | 0.7 | - | - | 0.8 | 3.4 | 1.6 | 1 | - | ||
| t(9;22) | 0.3 | - | - | 1.1 | 0.8 | 1 | - | ||||
| Complex | 4.2 | 17 | 7.3 | 6 | 6.4 | 2.3 | 0.8 | 10.8 | 14 | 10 | |
| Numerical abnormalities (%) | |||||||||||
| -5/del(5q) | 2.1 | 6.6 | 0.8 | 1 | 0.3 | 2.3 | - | 2.2 | 1 | 4.7 | 7 |
| -7/del(7q) | 4.5 | 7 | 1.2 | 1 | 0.3 | 1.1 | 0.8 | 3 | 3 | 7.2 | 7 |
| +8 | 6.8 | 7.3 | 3 | 2 | - | - | 3.3 | 7 | 5.2 | 10 | 9 |
| +11 | 2.1 | 1.66 | 1.6 | ||||||||
| +21 | 3.9 | - | - | - | - | - | 3 | 2 | |||
AML, Acute myeloid leukemia; abn, Abnormality; del, Deletion; inv, Inversion; t, Translocation